Dose and outcome of care in haemophilia - How do we define cost-effectiveness?

Haemophilia, Supplement

Volumn 10, Issue 4, 2004, Pages 216-220

  Fischer, K ^a,b   Van Den Berg, H M ^a   Thomas, R ^c   Kumar, S ^c   Poonnoose, P ^c   Viswabandya, A ^c   Mathews, V ^c   Kavitha, M L ^c   Bhattacharji, S ^c   Srivastava, A ^c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

Dose; Haemophilia; Outcome

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CRYOPRECIPITATE; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR CONCENTRATE;

ADOLESCENT; ADULT; ARTHROPATHY; ARTICLE; BLEEDING DISORDER; CLINICAL FEATURE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG DOSE REGIMEN; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH CARE PLANNING; HEMARTHROSIS; HEMOPHILIA; HUMAN; MAJOR CLINICAL STUDY; NETHERLANDS; PATIENT CARE; PRIORITY JOURNAL; SWEDEN; TREATMENT OUTCOME; UNITED STATES; WORLD HEALTH ORGANIZATION;

EID: 19944382461     PISSN: 13550691     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2004.01047.x     Document Type: Article

References (16)

1. Van den Berg HM, Fischer K, Mauser-Bunschoten EP et al. Long term outcome of individualised prophylactic treatment of children with severe haemophilia. Br J Haematol 2001; 107: 561-5.
2. Fischer K, Van der Bom JG, Mauser-Bunschoten EP et al. Changes in treatment strategies for severe haemophilia over the last 3 decades. effects on clotting factor consumption and arthropathy. Haemophilia 2001; 7: 446-52.
3. Pettersson H, Nilsson IM, Hedner U, Norehn K, Ahlberg A. Radiologic evaluation of prophylaxis in severe haemophilia. Acta Paediatr Scand 1981; 70: 565-70.
4. Manco Johnson MJ, Nuss R, Geraghty S, Funk S, Kilcoyne R. Results of secondary prophylaxis in children with severe haemophilia. Am J Hematol 1994; 47: 113-7.
5. Liesner RJ, Khair K, Hann IM. The impact of prophyactic treatment on children with severe haemophilia. Br Haematol 1996; 92: 973-8.
6. Fischer K, Van der Bom JG, Mauser-Bunschoten EP et al. Effects of postponing prophylactic treatment on long-term outcome in patients with severe haemophilia. Blood 2002; 99: 2337-41.
7. Löfqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients-a long-term follow-up. J Intern Med 1997; 241: 395-400.
8. Miners AH, Sabin CA, Tolley KH, Lee CA. The changing patterns of factor VIII (FVIII) and factor IX (FIX) clotting factor usage in a comprehensive care centre between 1980 and 1994. Haemophilia 1998; 4: 4-9.
9. Srivastava A. Dose and response in haemophilia: Optimization of factor replacement therapy. Br J Haematol 2004; 127: 12-15.
10. Dietrich S. Treatment of haemophilia bleeding problems with limited or no use of replacement therapy. Haemophilia 2000; 6 (Suppl. 1): 1-3.
11. Gilbert MS. Prophylaxis: musculoskeletal evaluation. Semin Haematol 1993; 30: 3-6.
12. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Int Med 1992; 232: 25-32.
13. Manco-Johnson MJ, Nuss R, Funk S, Murphy J. Joint evaluation instruments for children and adults with haemophilia. Haemophilia 2000; 6: 649-57.
14. Ljung RCR. Prophylactic infusion regimens in the management of hemophilia. Thromb Haemostat 1999; 82: 525-30.
15. Schramm W, Berger K. Economics of prophylactic treatment. Haemophilia 2003; 9: 111-6.
16. Miners AH, Sabin CA, Tolley KH, Lee CA. (1998) Assessing the effectiveness and cost-effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand's disease. J Int Med 1998; 244: 515-22.